Literature DB >> 31814640

Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.

Jennifer K Hay1, Victoria S Larson1.   

Abstract

The efficacy and toxicity of lomustine and prednisone for treating high-grade completely excised mast cell tumors (MCTs) was evaluated in a retrospective study of 15 dogs. Dogs were treated with lomustine (CCNU) at 70 mg/m2 every 4 weeks and prednisone at 0.5 to 1 mg/kg body weight PO daily. Eight dogs had treatment failures due to recurrence at the site of the initial surgery (2/15), de novo cutaneous MCT (4/15), or metastatic disease (2/15). The median overall survival time was 904 days, with 9 dogs alive at 1 year and 6 dogs alive after 2 years. All but 2 of the dogs had toxicity throughout their treatment protocol, with neutropenia (67%) and elevations in ALT (60%) being the most common; however, no dogs required hospitalization. The protocol was overall well-tolerated and lomustine/prednisone should be considered in the adjunctive treatment of high-grade mast cell tumors. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31814640      PMCID: PMC6855235     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  13 in total

1.  Association of hepatic necrosis with trimethoprim sulfonamide administration in 4 dogs.

Authors:  D C Twedt; K J Diehl; M R Lappin; D M Getzy
Journal:  J Vet Intern Med       Date:  1997 Jan-Feb       Impact factor: 3.333

2.  Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0.

Authors: 
Journal:  Vet Comp Oncol       Date:  2004-12       Impact factor: 2.613

3.  The prognosis following surgical removal of mastocytomas in dogs.

Authors:  D E Bostock
Journal:  J Small Anim Pract       Date:  1973-01       Impact factor: 1.522

4.  Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.

Authors:  D H Thamm; M M Turek; D M Vail
Journal:  J Vet Med Sci       Date:  2006-06       Impact factor: 1.267

5.  Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).

Authors:  D H Thamm; E A Mauldin; D M Vail
Journal:  J Vet Intern Med       Date:  1999 Sep-Oct       Impact factor: 3.333

6.  Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014).

Authors:  Damiano Stefanello; Paolo Buracco; Silvia Sabattini; Riccardo Finotello; Chiara Giudice; Valeria Grieco; Selina Iussich; Massimiliano Tursi; Timothy Scase; Stefano Di Palma; Giuliano Bettini; Roberta Ferrari; Marina Martano; Francesca Gattino; Mary Marrington; Monica Mazzola; Maria Elisabetta Vasconi; Maurizio Annoni; Laura Marconato
Journal:  J Am Vet Med Assoc       Date:  2015-04-01       Impact factor: 1.936

7.  Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior.

Authors:  M Kiupel; J D Webster; K L Bailey; S Best; J DeLay; C J Detrisac; S D Fitzgerald; D Gamble; P E Ginn; M H Goldschmidt; M J Hendrick; E W Howerth; E B Janovitz; I Langohr; S D Lenz; T P Lipscomb; M A Miller; W Misdorp; S Moroff; T P Mullaney; I Neyens; D O'Toole; J Ramos-Vara; T J Scase; F Y Schulman; D Sledge; R C Smedley; K Smith; P W Snyder; E Southorn; N L Stedman; B A Steficek; P C Stromberg; V E Valli; S E Weisbrode; J Yager; J Heller; R Miller
Journal:  Vet Pathol       Date:  2010-11-09       Impact factor: 2.221

8.  Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs.

Authors:  A K Patnaik; W J Ehler; E G MacEwen
Journal:  Vet Pathol       Date:  1984-09       Impact factor: 2.221

9.  Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs.

Authors:  Orna Kristal; Kenneth M Rassnick; John M Gliatto; Nicole C Northrup; John D Chretin; Kirsten Morrison-Collister; Susan M Cotter; Antony S Moore
Journal:  J Vet Intern Med       Date:  2004 Jan-Feb       Impact factor: 3.333

Review 10.  Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection.

Authors:  Dodd G Sledge; Joshua Webster; Matti Kiupel
Journal:  Vet J       Date:  2016-06-15       Impact factor: 2.688

View more
  2 in total

Review 1.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

2.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.